Oral DPD-inhibitory fluoropyrimidine drugs

ONCOLOGY

Volumn 14, Issue 10 SUPPL. 9, 2000, Pages 19-23

  Diasio, Robert B ^a,b  

^a Department of Pharmacology and Toxicology ^*  (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 UFT PROTOCOL; 1-UFT PROTOCOL; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG DERIVATIVE; EMITEFUR; FLUOROURACIL; FOLINIC ACID; OXIDOREDUCTASE; OXONIC ACID; PYRIDINE DERIVATIVE; S 1 (COMBINATION); TEGAFUR; URACIL;

BIOAVAILABILITY; DRUG ANTAGONISM; DRUG COMBINATION; DRUG RESISTANCE; HUMAN; ORAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL AVAILABILITY; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; LEUCOVORIN; OXIDOREDUCTASES; OXONIC ACID; PYRIDINES; TEGAFUR; URACIL;

EID: 0034304265     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Daher GC, Harris BE, Diasio RB: Metabolism of pyrimidine analogues and their nucleosides, in: Metabolism and Reactions of Anticancer Drugs, Vol. 1, in: The International Encyclopedia of Pharmacology and Therapeutics, chapter 2. Oxford, Pergamon Press, 1994.
2. Grem J: 5-Fluoropyrimidines, in Chabner BA, Longo DL, (eds): Cancer Chemotherapy and Biotherapy, pp 180-224. Philadelphia, Lippincott-Raven,1996.
3. Lu Z-H, Zhang R, Diasio RB: Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem 267: 17102-17109, 1992.
4. Harris BE, Song R, He Y, et al: Circadian rhythm of rat liver dihydropyrimidine dehydrogenase: Possible relevance to fluoropyrimidine chemotherapy. Biochem Pharm 37: 4759-4763, 1988.
5. Harris BE, Song R, Soong S-J, et al: Circadian variation of 5-fluorouracil catabolism in isolated perfused rat liver. Cancer Res 49:6610-6614, 1989.
6. Harris BE, Song R, Soong SJ, et al: Relationship of dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels: Evidence for circadian variation of 5-fluorouracil levels in cancer patients receiving protracted continuous infusion. Cancer Res 50: 197-201, 1990.
7. Levi F: Cancer chronotherapy. J Pharm Pharmacol 51:891-898, 1999.
8. Heggie GD, Sommadossi JP, Cross DS, et al: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203-2206, 1987.
9. Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53:5433-5438, 1993.
10. Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human liver: Population characteristics and clinical implication in 5-FU chemotherapy. Clin Pharmacol Ther 58: 512-522, 1995.